CDC42BPA
MOLECULAR TARGETCDC42 binding protein kinase alpha
CDC42BPA (CDC42 binding protein kinase alpha) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CDC42BPA
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | sb 203580 | 4.92 | 136 |
| 2 | alvocidib | 4.52 | 91 |
| 3 | foretinib | 4.34 | 76 |
| 4 | vandetanib | 4.30 | 73 |
| 5 | pi 103 | 4.17 | 64 |
| 6 | doramapimod | 4.06 | 57 |
| 7 | lestaurtinib | 3.04 | 20 |
| 8 | torin1 | 2.40 | 10 |
| 9 | decernotinib | 2.20 | 8 |
| 10 | ucn 01 | 1.79 | 5 |
| 11 | sar 407899 free base | 1.79 | 5 |
| 12 | Dasatinib | 1.10 | 2 |
| 13 | torin 1 | 1.10 | 2 |
| 14 | alsterpaullone | 0.69 | 1 |
| 15 | kenpaullone | 0.69 | 1 |
About CDC42BPA as a Drug Target
CDC42BPA (CDC42 binding protein kinase alpha) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented CDC42BPA interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CDC42BPA inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.